Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome.
The purpose of this study is to report the experience of using abbreviated rasburicase dosing for adult patients at risk for developing hyperuricemia secondary to tumor lysis syndrome. All patients who received rasburicase from January 2003 through March 2004 were identified, and a retrospective chart review was conducted. Thirteen patients received >/= 1 dose of rasburicase for the prevention or treatment of hyperuricemia. Of these patients, 8 patients received 1 dose, 3 patients received 2 doses, and 2 patients received 3 doses of rasburicase. All 13 patients experienced normalization of plasma uric acid levels within 24 hours (mean uric acid decreased from 9.1 mg/dL to 0.68 mg/dL). Mean serum creatinine decreased from 2.3 mg/dL to 1.6 mg/dL. No patients required hemodialysis. Our experience supports that abbreviated courses of rasburicase are effective in managing hyperuricemia in patients at risk for tumor lysis syndrome.